To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on June 30, 2025Data in Crores of INR
Revenue
425.24-6.59% from last year
Operating profits
28.58-48.08% from last year
Net income
11.40-68.47% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Net worth1156.23847.23752.91578.56424.75284.06253.09225.94196.26300.28287.48297.11299.88
Fixed assets488.51307.35266.97251.80224.52216.37236.21264.29271.80296.72322.48368.08409.46
Debt79.3929.0025.1618.5717.0513.47131.6014.5648.9967.5180.8989.28111.23
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Operating32.0673.37-91.17-60.2450.8311.0217.3763.4140.7350.0750.7033.5233.64
Investing -321.51-83.30-46.51-31.68-70.35-12.46-13.05-26.93-13.60-27.30-31.65-0.80-2.83
Financing 299.895.20143.5466.3347.275.49-0.44-37.77-23.72-27.26-19.31-29.14-29.79

Financial ratios

Profitability ratiosinfo2
ROA7.68%
ROE11.78%
ROCE15.48%
EPS2.15%
Net profit margin6.51%
Operating profit margin10.62%
Dividend per share0.2%
Operational ratiosinfo2
Quick ratio1.72%
Current ratio2.32%
Interest coverage19.59%
Assets turnover1.18%
Debt to equity0.07%
Valuation ratiosinfo2
P/E ratio29.01%
P/B ratio2.3%
Dividend yield0.41%
EV/EBITDA
Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs Home Diagnostics Formulations and OTC products. The plant at Masulkhana is for manufacture of Loratadine an anti-allergy drug - internationally known as Claritin. Diagnostics business Morepen has a formidable presence in Blood Glucose Monitors and Blood Pressure Monitors in the domestic markets.
personal

Grow your wealth with more research recommendations

+91